Cargando…
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial
INTRODUCTION: Acute kidney injury (AKI) is a well-recognised complication of critical illness which is of crucial importance for morbidity, mortality and health resource utilisation. Renal replacement therapy (RRT) inevitably entails an escalation of treatment complexity and increases costs for thos...
Autores principales: | Meersch, Melanie, Küllmar, Mira, Wempe, Carola, Kindgen-Milles, Detlef, Kluge, Stefan, Slowinski, Torsten, Marx, Gernot, Gerss, Joachim, Zarbock, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347902/ https://www.ncbi.nlm.nih.gov/pubmed/30670518 http://dx.doi.org/10.1136/bmjopen-2018-024411 |
Ejemplares similares
-
Analysis of Leukocyte Recruitment in Continuous Veno-Venous Hemofiltration with Regional Citrate vs. Systemic Heparin Anticoagulation
por: Margraf, Andreas, et al.
Publicado: (2022) -
Biomarker-guided implementation of the KDIGO guidelines to reduce the occurrence of acute kidney injury in patients after cardiac surgery (PrevAKI-multicentre): protocol for a multicentre, observational study followed by randomised controlled feasibility trial
por: Küllmar, Mira, et al.
Publicado: (2020) -
Ionized calcium measurements during regional citrate anticoagulation in CRRT: we need better blood gas analyzers
por: Kindgen-Milles, Detlef, et al.
Publicado: (2015) -
Regional citrate anticoagulation in high-volume continuous venovenous hemodialysis
por: Kalb, R, et al.
Publicado: (2011) -
Biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2 trial): study protocol for an international, prospective, randomised controlled multicentre trial
por: von Groote, Thilo, et al.
Publicado: (2023)